reuptake inhibitor

A reuptake inhibitor is a compound that blocks the process by which a neuron recycles neurotransmitters after releasing them into the synapse. Normally, dedicated transporter proteins on the presynaptic neuron collect released molecules and pull them back inside, ending the signal cleanly. A reuptake inhibitor occupies or obstructs those transporters, leaving the neurotransmitter in the synaptic gap for longer and at higher concentrations.

The term describes a mechanism, not a single drug. A substance may inhibit reuptake of serotonin, dopamine, norepinephrine, or some combination — and its effects follow directly from which transporter it targets.

How it works · its role

Each major monoamine neurotransmitter has its own dedicated transporter: SERT carries serotonin, DAT carries dopamine, and NET carries norepinephrine. A reuptake inhibitor binds to one or more of these proteins and blocks the channel through which the neurotransmitter would normally re-enter the neuron.

The signal is not amplified by creating extra neurotransmitter — it is prolonged. By slowing removal, the inhibitor raises the effective concentration at postsynaptic receptors, increasing how long and how strongly those receptors are activated. With sustained exposure, the brain often compensates by gradually reducing receptor density or sensitivity, which is why many reuptake inhibitors take days to weeks to reach their full effect.

Relevance to substances & effects

Reuptake inhibition is one of the most common mechanisms through which psychoactive substances act. SSRIs — selective serotonin reuptake inhibitors — target SERT specifically, gradually raising synaptic serotonin to produce the mood-stabilising effects used in treating depression and anxiety. SNRIs extend that action to norepinephrine as well.

Cocaine and many stimulants block DAT and NET simultaneously, producing sharp increases in dopamine and norepinephrine that account for the characteristic stimulant and euphoric character. MDMA acts partly as a reuptake inhibitor, particularly at SERT, while also forcing active neurotransmitter release — which is why its subjective profile differs sharply from an SSRI despite sharing part of the mechanism.

Because different reuptake inhibitors can target the same transporters, combining them — or layering them with releasers or direct agonists — stacks their effects on shared pathways.

Clinical · risk note

Combining two or more serotonergic reuptake inhibitors, or pairing one with a drug that releases or directly agonises serotonin, can push synaptic serotonin to dangerous levels. This is a primary route to serotonin syndrome — a potentially serious condition involving agitation, rapid heartbeat, raised body temperature, and muscle rigidity.

The risk is especially acute when a monoamine oxidase inhibitor (MAOI) is taken alongside any serotonin reuptake inhibitor, since MAOIs prevent serotonin breakdown while the inhibitor prevents its clearance from the synapse. Such combinations are flagged as contraindicated throughout the encyclopedia.